US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>The company priced 8.75 million shares at $16.00, upsized from its original filing, and opened at $16.12—a 0.8% premium at first trade.</li>
<li>Amid broad biotech sector volatility and light volume, MAZE dropped to a low of $6.71 in April but has since rebounded closer to the IPO price. </li>
<li>For Maze, the next chapter will be shaped by clinical data with readouts expected later this year and in the first quarter of 2026. </li>
</ul>


The company priced 8.75 million shares at $16.00, upsized from its original filing, and opened at $16.12—a 0.8% premium at first trade.
Amid broad biotech sector volatility and light volume, MAZE dropped to a low of $6.71 in April but has since rebounded closer to the IPO price. 
For Maze, the next chapter will be shaped by clinical data with readouts expected later this year and in the first quarter of 2026. 


Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead